[Cl:1][C:2]1[N:3]=[CH:4][NH:5][C:6]=1[Cl:7].[OH-].[K+].[Br:10][CH2:11][C:12]1[CH:21]=[N:20][C:19]2[C:14](=[CH:15][CH:16]=[CH:17][CH:18]=2)[N:13]=1>C(#N)C>[Br-:10].[N:13]1[C:14]2[C:19](=[CH:18][CH:17]=[CH:16][CH:15]=2)[N:20]=[CH:21][C:12]=1[CH2:11][N+:3]1[C:2]([Cl:1])=[C:6]([Cl:7])[N:5]([CH2:11][C:12]2[CH:21]=[N:20][C:19]3[C:14](=[CH:15][CH:16]=[CH:17][CH:18]=3)[N:13]=2)[CH:4]=14,5-dichloroimidazole (1.37 g, 10 mmol) will be dissolved in a minimum amount of acetonitrile and potassium hydroxide (0.62 g, 11 mmol) will be added. The mixture will be stirred at reflux until the potassium hydroxide is consumed, approximately 30 min. 2-(Bromomethyl)quinoxaline (2.23 g, 10.0 mmol) will be added and the mixture will be returned to reflux for 3 h. The mixture will be filtered hot to remove the potassium bromide generated. A second addition of 2-(bromomethyl)quinoxaline (2.23 g, 10.0 mmol) will be made to the reaction solution, which will be returned to reflux for 6 h. Removal of the volatile components under reduced pressure should yield the product.